Hematology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia Therapy
Reports summarize acute myeloid leukemia therapy study results from Roswell Park Cancer Institute, Department of Medicine
April 16th, 2007
New investigation results, "The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells," are detailed in a study published in Investigational New Drugs. "The synthetic 4'-O-benzylated doxorubicin analog WP744 was designed to abrogate transport by the multidrug resistance (MDR)-associated ATP-binding cassette (ABC) proteins P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1)," researchers in the United States report. "We compared its uptake and cytotoxicity with those of doxorubicin and daunorubicin in cell...
Source: Hematology Week (2007-04-16)
|
